TuisALNOV • EPA
Novacyt SA
€0,73
30 Sep., 13:19:11 GMT+2 · EUR · EPA · Vrywaring
AandeelFR-gelyste effek
Vorige sluiting
€0,75
Dagwisseling
€0,72 - €0,76
Jaarwisseling
€0,45 - €1,59
Markkapitalisasie
52,40 m EUR
Gemiddelde volume
2,09 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(GBP)Des. 2023J/J-verandering
Inkomste
4,12 m81,82%
Bedryfskoste
12,52 m48,31%
Netto inkomste
-9,97 m-17,10%
Netto winsgrens
-242,0435,59%
Wins per aandeel
EBITDA
-7,10 m-41,10%
Effektiewe belastingkoers
2,93%
Totale bates
Totale aanspreeklikheid
(GBP)Des. 2023J/J-verandering
Kontant en korttermynbeleggings
44,06 m-49,34%
Totale bates
133,82 m-5,03%
Totale aanspreeklikheid
46,57 m81,32%
Totale ekwiteit
87,24 m
Uitstaande aandele
70,63 m
Prys om te bespreek
0,60
Opbrengs op bates
-21,46%
Opbrengs op kapitaal
-28,44%
Netto kontantverandering
(GBP)Des. 2023J/J-verandering
Netto inkomste
-9,97 m-17,10%
Kontant van bedrywe
-9,65 m-59,94%
Kontant van beleggings
-7,47 m-3 853,70%
Kontant van finansiering
-1,72 m-1 360,85%
Netto kontantverandering
-18,84 m-197,44%
Beskikbare kontantvloei
-3,81 m-56,02%
Meer oor
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Gestig
2006
Werknemers
237
Search
Vee soektog uit
Maak soekkassie toe
Google-programme
Hoofkieslys